John Kingrey, MD
Pulmonary Disease · Oklahoma City, OKNPI 1689863953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $240,638 of the $332,178 with a category attached, or 72.4%. 21 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 49.5% of the total. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $641.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$164K
- United Therapeutics Corporation$112K
- Merck$29K
- Bayer$25K
- Boehringer Ingelheim$351
- Sandoz$215
- plus $1K from 15 others
Across 222 payments — averaging $9371.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- United Therapeutics Corporation$701K
- Janssen Research & Development, LLC$75K
- Actelion Pharmaceuticals, Ltd$40K
What the payments were for
- Consulting fees$55,23617%
- Speaking & faculty fees$240,63872%
- Travel & lodging$17,6435%
- Food & beverage$12,0834%
- Education$6,5772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 207 | $164,373 |
| United Therapeutics Corporation | 168 | $112,063 |
| Merck | 44 | $28,728 |
| Bayer | 33 | $25,419 |
| Boehringer Ingelheim | 15 | $351 |
| Sandoz | 9 | $215 |
| Novo Nordisk | 7 | $195 |
| Abbott | 6 | $164 |
| Insmed, Inc. | 4 | $159 |
| Genentech USA, Inc. | 6 | $151 |
| Abiomed | 2 | $77 |
| Inogen, Inc. | 5 | $52 |
| Johnson & Johnson(2 entities) | 3 | $50 |
| GSK | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 1 | $39 |
| Boston Scientific | 1 | $22 |
| Amgen | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Veran Medical Technologies, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$332,178 in reported general payments places this provider in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 800 | $9,973,163 |
| UptraviSelexipag | 351 | $7,728,354 |
| Orenitram ErTreprostinil Diolamine | 378 | $5,262,015 |
| AdempasRiociguat | 376 | $5,113,697 |
| Tyvaso DpiTreprostinil | 205 | $4,888,179 |
| WinrevairSotatercept-Csrk | 66 | $1,345,059 |
| OfevNintedanib Esylate | 67 | $983,244 |
| Ambrisentan | 189 | $486,157 |
| LetairisAmbrisentan | 17 | $218,745 |
| TracleerBosentan | 14 | $178,559 |
| Tadalafil | 476 | $153,463 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $153,208 |
| EliquisApixaban | 173 | $137,154 |
| Bosentan | 36 | $128,630 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $66,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer, Bosentan | $164,373 | $18,008,7051,201 claims |
| BayerAdempas | $25,419 | $5,113,697376 claims |
| MerckWinrevair | $28,728 | $1,345,05966 claims |
| Boehringer IngelheimOfev, Jardiance | $351 | $1,020,311120 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $40 | $106,783164 claims |
| SandozEnoxaparin Sodium | $215 | $2,03214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
- Azhar KhanOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.